Research & Development



  只要皇帝指揮的戰斗能夠勝利,哪怕他帶來的一萬兩千人全部戰死也無關緊要。   這才是我一直追問所有細節的原因。”2014网络彩票牌照   他是白狼口烽燧上資格最老的軍卒,也是軍功最卓著的一個,就因為離奇的身世,讓他數十年來都不得晉升,至今還只是一個什長。3.6亿中奖彩票   劉陵笑道︰“自然是你的,這是你通過艱苦卓絕的斗爭得來的權力,如何能不是你的呢?”   “去病如果想要這個女人,他早就要了,所以,你就不用等了。”24日福利彩票出奖号码   “坐不住也要坐啊,十六了,還不如你這個十二的來的安靜,好女子就該是你這樣的,要她識文斷字也做不好,唉……愁死老夫了。再過兩年,等劉婆老的干不動了,家主說這一攤子事情就該你接手,你看看,一樣都是跟著家主的大丫頭,區別怎麼這麼大呢。都是早年間跟著丑庸那個蠢丫頭學壞了。”

Our discovery and development platforms for drug and cell-based therapies allow us to both create and retain significant value within our therapeutic franchise areas of cancer and inflammatory diseases. Scientists and physicians at Celgene are the driving force behind our success, enabling target-to-therapeutic platforms that integrate both small-molecule and cell-based therapies.

Connect? Registries

The Connect??Registries are observational, hematologic patient registry studies in Multiple Myeloma (Connect?MM), Chronic Lymphocytic Leukemia (Connect?CLL) and Myelodysplastic Syndromes/Acute Myeloid Leukemia (Connect?MDS/AML) and are sponsored by Celgene Corporation. These studies are designed to observe the routine care of patients through the course of their disease. Unlike clinical trials, registries do not require or provide any specific medications or healthcare services, but leave those decisions to the treating doctors and their patients.
Connect? Registries logo